Ian Thomas
Senior Trial Manager in Blood Cancer
- Email:
- thomasif@cardiff.ac.uk
- Telephone:
- +44 (0)29 2251 0531
2018
- Burnett, A. K.et al. 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32, pp. 2693-2714. (10.1038/s41375-018-0148-3)
2017
- Knapper, S.et al. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9), pp. 1143-1154. (10.1182/blood-2016-07-730648)
2016
- Burnett, A. K.et al. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101(6), pp. 724-731. (10.3324/haematol.2016.141937)
2015
- Burnett, A. K.et al. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25), pp. 3878-3885. (10.1182/blood-2015-01-623447)
- Khan, N.et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
- Dennis, M.et al. 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125(19), pp. 2923-2932. (10.1182/blood-2014-10-608117)